STMN1 expression is associated with chemotherapy and immunotherapy efficacy in biliary tract cancer - Takeaways - MDSpire

Association of STMN1 Expression with the Effectiveness of Chemotherapy and Immunotherapy in Biliary Tract Cancer

  • By

  • Changcheng Wang

  • Lingxi Nan

  • Qingyang Meng

  • Chengjia Lu

  • Wenkai Cui

  • Tao Suo

  • Shulong Zhang

  • Houbao Liu

  • Yueqi Wang

  • Wenqing Qiu

  • Xiaobo Bo

  • July 20, 2026

Share

  • 1

    STMN1 expression correlates with inferior overall survival in biliary tract cancer patients.

  • 2

    STMN1 serves as an independent adverse prognostic biomarker for overall survival in biliary tract cancer.

  • 3

    High STMN1 expression predicts superior responses to immune checkpoint blockade in biliary tract cancer patients.

  • 4

    Patients with low STMN1 expression benefit significantly from gemcitabine-based adjuvant chemotherapy.

  • 5

    Elevated STMN1 expression is linked to immune response activation and T-cell infiltration in the tumor microenvironment.

Original Source(s)

STMN1 expression is associated with chemotherapy and immunotherapy efficacy in biliary tract cancer

  • by Changcheng Wang, Lingxi Nan, Qingyang Meng, Chengjia Lu, Wenkai Cui, Tao Suo, Shulong Zhang, Houbao Liu, Yueqi Wang, Wenqing Qiu, Xiaobo Bo

  • July 20, 2026

Related Content

National trends in bone-metastatic prostate cancer mortality in the United States, 1999–2024: a multiple-cause-of-death analysis with projections to 2040

Non-anticoagulant heparins: glycan-mediated immune modulation and therapeutic applications

Multitask learning for early treatment response and survival prediction in lung cancer radiotherapy using sequential CBCT imaging